Navigation Links
Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
Date:2/17/2009

MEXICO CITY, Feb. 17 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), announced today its fourth quarter and twelve month results for the periods ended December 31, 2008. All figures included herein are audited(1) and were prepared in accordance with Mexican GAAP; 2008 figures are stated in nominal Mexican pesos and 2007 figures have been restated in constant Mexican pesos as of December 31, 2007. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

    4Q08 Highlights (vs. 4Q07)
    -- Net Sales reached Ps. 749.2 million, an increase of 33.6%
    -- Gross Profit was Ps. 545.5 million, an increase of 37.6%
    -- EBITDA(2) increased 27.3% to Ps. 212.1 million
    -- Consolidated Net Income rose 92.8% to Ps. 192.7 million
    -- Earnings Per Share(3) increased 34.0% to Ps. 0.97 during the fourth
       quarter
    -- International Net Sales rose 662.9%, to Ps. 113.4 million
    -- During the fourth quarter, Genomma successfully launched eight products
       under six existing brands (Base Brands(4) and Prior Year Launches(5))
       as part of our line extension strategy
    -- The Company also launched five products under four New Brands(6),
       as part of its new product launch plan during the fourth quarter
    -- As of December 31, 2008 the Company had a net cash position of
       Ps. 1,291.0 million

For the complete version of this earnings report, please visit: http://www.genommalab.com

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share, through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

The Company had net sales of Ps. 2,629.4 million and EBITDA of Ps. 691.1 million in 2008. Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this release and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    (1) Audited Financial Statements have not been presented to the
        shareholders' meeting for approval.
    (2) EBITDA is defined as earnings before interest, taxes, depreciation and
        amortization.
    (3) Earnings per share is for the last 12 months. Earnings per share were
        calculated using the weighted average of shares outstanding for
        the period.
    (4) As defined in the full earnings report.
    (5) As defined in the full earnings report.
    (6) As defined in the full earnings report.

    Investor Relations Contact:
    Oscar Villalobos
    Tel: +52 (55) 5081 0000 Ext. 4250
    E-mail: inversion@genommalab.com

    In New York:
    i-advize Corporate Communications, Inc.
    Tel: (212) 406-3692
    E-mail: genomma@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Internacional Acquires UNIGASTROZOL
4. Genomma Lab Announces 2009 Earnings Guidance
5. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
6. Genomma Lab Announces Initiation of Stock Repurchase Fund
7. Genomma Lab, New Participant in Market-Maker Program
8. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
9. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pennsylvania Cable Network (PCN) during the summer of 2016. The program was made ... by the United States Department of Health and Human Services Administration. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Allergy Diagnostics ... products and tests that are used to determine ... peanuts, milk, or drugs etc. in the samples ... the immune system. The report on global allergy ... of the market. The report consists of an ...
(Date:12/8/2016)... Connecticut , 8 de dezembro de 2016  A Mederi Therapeutics ... terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: